Related Experiment Videos
Parkinsonism by haloperidol and piribedil
Psychopharmacology
|October 31, 1978
Summary
Combining haloperidol with piribedil (a dopamine agonist) in schizophrenic patients significantly increased parkinsonism symptoms. This suggests piribedil potentiates haloperidol
Area of Science:
- Neuroscience
- Psychopharmacology
- Clinical Psychiatry
Background:
- Schizophrenia treatment often involves antipsychotics like haloperidol.
- Dopamine agonists, such as piribedil, are used in other neurological conditions.
- Extrapyramidal side effects are common with antipsychotic medications.
Purpose of the Study:
- To investigate the combined effects of haloperidol and piribedil on schizophrenic patients.
- To understand the interaction between dopamine agonists and antipsychotics regarding side effects.
Main Methods:
- Three groups of schizophrenic patients were studied.
- Treatments included haloperidol alone, low-dose piribedil alone, and a combination therapy.
- Patients were monitored for extrapyramidal symptoms, specifically parkinsonism.
Main Results:
- The combination of haloperidol and piribedil induced marked rigidity and akinesia in all patients.
- Patients receiving haloperidol or piribedil alone exhibited mild or no parkinsonism symptoms.
- The combination primarily caused an akinetic-hypertonic syndrome with minimal tremors.
Conclusions:
- Low-dose dopamine agonists can potentiate the extrapyramidal side effects of haloperidol.
- This potentiation may occur via self-inhibitory dopamine receptors, blocking compensatory dopaminergic activity.
- Careful consideration of combined dopaminergic and neuroleptic therapy is warranted.